ArticleTherapeutic delivery2011
The effect of cholesterol domains on PEGylated liposomal gene delivery in vitro.
Article in Therapeutic delivery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Synthesis of ionizable lipopolymers using split-Ugi reaction for pulmonary delivery of various size RNAs and gene editing.Nature communications · 2025Article
- Redox-sensitive doxorubicin liposome: a formulation approach for targeted tumor therapy.Scientific reports · 2022Article
- Cytotoxic Potential, Metabolic Profiling, and Liposomes ofInternational journal of nanomedicine · 2021Article
- Cholesterol-rich lipid-mediated nanoparticles boost of transfection efficiency, utilized for gene editing by CRISPR-Cas9.International journal of nanomedicine · 2019Article
- Nanoparticle uptake by circulating leukocytes: A major barrier to tumor delivery.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Lipid-Mediated Targeting with Membrane-Wrapped Nanoparticles in the Presence of Corona Formation.ACS nano · 2016Article
- Relating toxicity to transfection: using sphingosine to maintain prolonged expression in vitro.Molecular pharmaceutics · 2015Article
- α, ω-Cholesterol-functionalized low molecular weight polyethylene glycol as a novel modifier of cationic liposomes for gene delivery.International journal of molecular sciences · 2014Article
- Examination of the specificity of tumor cell derived exosomes with tumor cells in vitro.Biochimica et biophysica acta · 2014Article
- Mechanistic evaluation of the transfection barriers involved in lipid-mediated gene delivery: interplay between nanostructure and composition.Biochimica et biophysica acta · 2014Article
- Poly(ethylene glycol)-cholesterol inhibits L-type Ca2+ channel currents and augments voltage-dependent inactivation in A7r5 cells.PloS one · 2014Article
- Questioning the Use of PEGylation for Drug Delivery.Drug delivery and translational research · 2013Article
- The effects of lipoplex formulation variables on the protein corona and comparisons with in vitro transfection efficiency.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Selective biophysical interactions of surface modified nanoparticles with cancer cell lipids improve tumor targeting and gene therapy.Cancer letters · 2013Article
- Camptothecin-Loaded Liposomes with α-Melanocyte-Stimulating Hormone Enhance Cytotoxicity Toward and Cellular Uptake by Melanomas: An Application of Nanomedicine on Natural Product.Journal of traditional and complementary medicine · 2013Article
- Ligands located within a cholesterol domain enhance gene delivery to the target tissue.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
aimPEGylated components have been widely used to reduce particle aggregation in serum and extend circulation lifetime for lipid- and polymer-based gene-delivery systems. However, PEGylation is known to interfere with cell interaction and intracellular trafficking, resulting in decreased biological activity. In the present study, the effect of cholesterol domains on PEGylated liposome-mediated gene delivery was evaluated by PEGylating formulations with and without a cholesterol domain, and also by altering the location of PEG on the particle surface (i.e., within or excluded from the domain). MATERIALS AND
methodsLipoplexes formulated with PEG-cholesterol or PEG-diacyl lipid were used to transfect various cell lines, including human and mouse cancer cells. Cellular uptake of lipoplexes was also quantified and compared with the transfection results.
resultsOur findings are consistent with previous work demonstrating that PEGylation reduces transfection rates; however, formulations in which PEG was incorporated into the cholesterol domain did not exhibit this detrimental effect. In some cell lines, the incorporation of PEG into the domain actually increased transfection rates, despite no enhancement of cellular uptake. DISCUSSION: These results suggest that the adverse alterations in intracellular trafficking that are a consequence of PEGylation may be avoided by utilizing delivery vehicles that allow PEG to partition into a cholesterol domain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.